Key result
Novel conduction system leadless pacemaker demonstrates feasible early safety and electrical performance through 6 months.
Design
Early feasibility study (LEAP2)
Follow-up
3 and 6 months
Answers are grounded in this paper and cite their sources.
Supports further development of leadless conduction system pacing; leaves open safety, efficacy, and adoption pending larger randomized trials.
Leadless conduction system pacing (CSP) combines physiologic activation with the benefits of leadless pacing. Implant and 1-month results from an early feasibility study (LEAP2- NCT07287423) were previously reported; herein we report the first mid-term (3- and 6-month) evaluation of safety and electrical performance.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) studied this question. A novel leadless pacemaker for conduction system pacing was evaluated for 3- and 6-month safety and electrical performance in the LEAP2 early feasibility study.
Synapse has enriched 10 related papers. Consider them for comparative context: